Health Insurance (Section 3C Co‑Dependent Pathology Services) Determination 2018
made under subsection 3C(1) of the
Health Insurance Act 1973
Compilation No. 26
Compilation date: 1 July 2026
Includes amendments: F2026L00523 and F2026L00632
About this compilation
This compilation
This is a compilation of the Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018 that shows the text of the law as amended and in force on 1 July 2026 (the compilation date).
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au).
Application, saving and transitional provisions
If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Editorial changes
For more information about any editorial changes made in this compilation, see the endnotes.
Presentational changes
The Legislation Act 2003 provides for First Parliamentary Counsel to make presentational changes to a compilation. Presentational changes are applied to give a more consistent look and feel to legislation published on the Register, and enable the user to more easily navigate those documents.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. Any modifications affecting the law are accessible on the Register.
Self‑repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
Contents
1. Name of Determination
3. Authority
5. Definitions
5A. Indexation
6. Treatment of relevant services
Schedule 1 – Relevant Services
Endnotes
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
1. Name of Determination
This Determination is the Health Insurance (Section 3C Co‑Dependent Pathology Services) Determination 2018.
3. Authority
This Determination is made under subsection 3C(1) of the Health Insurance Act 1973.
5. Definitions
(1) In this Determination:
Act means the Health Insurance Act 1973.
relevant provisions means all provisions, of the Act and regulations made under the Act, and the National Health Act 1953 and regulations made under the National Health Act 1953, relating to medical services, professional services or items.
relevant service means a health service, as defined in subsection 3C(8) of the Act, that is specified in a Schedule.
Pathology services table means the table prescribed under subsection 4A(1) of the Act.
Pharmaceutical Benefits Scheme means the scheme for the supply of pharmaceutical benefits established under Part VII of the National Health Act 1953.
Schedule means a Schedule to this Determination.
Note: The following terms are defined in subsection 3(1) of the Act:
clinically relevant service
pathology services table
item
professional service
(2) Unless the contrary intention appears, a reference in this Determination to a provision of the Act or the National Health Act 1953 or regulations made under the Act or under the National Health Act 1953 as applied, adopted or incorporated in relation to specifying a matter is a reference to those provisions as in force from time to time and any other reference to provisions of an Act or regulations is a reference to those provisions as in force from time to time.
5A. Indexation
(1) At the start of 1 July 2026 (the indexation time), each amount covered by subsection (2) is replaced by the amount worked out using the following formula:
Note: The indexed fees could in 2026 be viewed on the Department of Health, Disability and Ageing’s MBS Online website (www.mbsonline.gov.au).
(2) The amounts covered by this subsection are the fee for each item in Group P5 (tissue pathology services).
(3) An amount worked out under subsection (1) is to be rounded up or down to the nearest 5 cents (rounding down if the amount is an exact multiple of 2.5 cents).
6. Treatment of relevant services
(1) For subsection 3C(1) of the Act a relevant service, provided in accordance with this Determination and as a clinically relevant service, is to be treated, for the relevant provisions, as if:
(a) it were both a professional service and a pathology service; and
(b) there were an item in Groups P2, P5 or P7 of the pathology services table that:
(i) related to the service; and
(ii) specified for the service a fee in relation to each State, being the fee specified in Schedule 1 in relation to the service.
Schedule 1 – Relevant Services
Group P2—Chemical | |||
Item | Description | Fee ($) | |
66520 | Fibroblast growth factor 23 quantification in serum or plasma, requested by a specialist or consultant physician to determine eligibility for a relevant treatment listed on the Pharmaceutical Benefits Scheme | 90.00 | |
Group P5—Tissue pathology | |||
Item | Description | Fee ($) | |
72814 | Immunohistochemical examination by immunoperoxidase or other labelled antibody techniques using the programmed cell death ligand 1 (PD‑L1) antibody of tumour material from a patient diagnosed with: (a) non‑small cell lung cancer; or (b) recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx; or (c) locally recurrent unresectable or metastatic triple‑negative breast cancer. | 76.30 | |
Group P7—Genetics | ||
Item | Description | Fee ($) |
73295 | Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme (PBS), in a patient with: (a) advanced (FIGO III‑IV) high‑grade serous or high‑grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible; or (b) breast cancer. Applicable once per lifetime | 1,200.00 |
73301 | A test of tumour tissue from a patient with advanced (FIGO III‑IV), high grade serous or high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to treatment with a poly (adenosine diphosphate [ADP]‑ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS) Applicable once per primary tumour diagnosis | 1,200.00 |
73302 | Characterisation of germline gene variants including copy number variants, in BRCA1 or BRCA2 genes, in a patient who has had a pathogenic or likely pathogenic variant identified in either gene by tumour testing and who has not previously received a service to which items 73295, 73296 or 73297 applies, requested by a specialist or consultant physician Applicable once per primary tumour diagnosis Note: Items 73296 and 73297 are in the pathology services table. | 400.00 |
73303 | A test of tumour tissue from a patient with metastatic castration‑resistant prostate cancer, including subsequent characterisation of germline gene variants should tumour tissue testing undertaken during the same service be inconclusive, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to a relevant treatment under the Pharmaceutical Benefits Scheme; Applicable once per primary tumour diagnosis | 1,000.00 |
73304 | Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with metastatic castration‑resistant prostate cancer, for whom testing of tumour tissue is not clinically feasible, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; Applicable once per lifetime | 1,000.00 |
73307 | A test of tumour tissue from a patient with advanced (FIGO III‑IV), high‑grade serous or other high‑grade ovarian, fallopian tube or primary peritoneal carcinoma, requested by a specialist or consultant physician, if the test is: (a) to determine eligibility with respect to homologous recombination deficiency (HRD) status, including BRCA1 or BRCA2 status, to provide access to poly (adenosine diphosphate [ADP]‑ribose) polymerase (PARP) inhibitor therapy under the Pharmaceutical Benefits Scheme; and (b) including a service described in item 73301 Applicable once per primary tumour diagnosis | 3,000.00 |
73319 | Detection in tumour tissue of isocitrate dehydrogenase 1 (IDH1) variant status, in a patient with histologically confirmed cholangiocarcinoma, to determine eligibility for a relevant treatment listed under the Pharmaceutical Benefits Scheme.
Applicable only once per lifetime | 340.00 |
73329 | A nucleic acid-based multi-gene panel test of tumour tissue from a patient with cholangiocarcinoma requested by, or on behalf of, a specialist or consultant physician, if the test is to: (a) detect at least IDH1 variant status, and (b) detect the fusion or rearrangement status of at least FGFR2; and (c) determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme including a service described in item 73319. Applicable once per lifetime | 800.00 |
73332 | An in situ hybridisation (ISH) test of tumour tissue from a patient with breast cancer requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to human epidermal growth factor receptor 2 (HER2) gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme or the Herceptin Program are fulfilled. | 315.40 |
73336 | A test of tumour tissue from a patient with stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib, vemurafenib or encorafenib under the Pharmaceutical Benefits Scheme are fulfilled | 230.95 |
73337 | A test of tumour tissue from a patient with a new diagnosis of non‑small cell lung cancer, requested by, or on behalf of, a specialist or consultant physician, if the test is: (a) for epidermal growth factor receptor (EGFR) status to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73438 applies | 397.35 |
73338 | A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if: (a) requirements relating to rat sarcoma oncogene (RAS) gene variant status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme are fulfilled, if: (i) the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4; or (ii) a clinically‑relevant RAS variant is detected; and, in cases where no RAS variant is detected: (b) the requirements relating to BRAF V600 gene variant status for access to encorafenib under the Pharmaceutical Benefits Scheme are fulfilled. | 362.60 |
73341 | Fluorescence in situ hybridisation (FISH) test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by a specialist or consultant physician, if the test is: (a) for ALK gene rearrangement status to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73439 applies | 400.00 |
73342 | An in situ hybridisation (ISH) test of tumour tissue from a patient with metastatic adenocarcinoma of the stomach or gastro‑oesophageal junction, with documented evidence of human epidermal growth factor receptor 2 (HER2) overexpression by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+ on the same tumour tissue sample, requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to HER2 gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme are fulfilled. | 315.40 |
73344 | Fluorescence in situ hybridization (FISH) test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by a specialist or consultant physician, if the test is: (a) for ROS1 gene arrangement status to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73439 applies | 400.00 |
73351 | A test of tumour tissue that is derived from a new sample from a patient with locally advanced (Stage IIIb) or metastatic (Stage IV) non‑small cell lung cancer (NSCLC), who has progressed on or after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). The test is to be requested by a specialist or consultant physician, to determine if the requirements relating to EGFR T790M gene status for access to osimertinib under the Pharmaceutical Benefits Scheme are fulfilled. | 397.35 |
73430 | Fluorescence in‑situ hybridisation (FISH) test of tumour tissue from a patient with locally advanced or metastatic solid tumour, if: (a) the tumour is at risk of being caused by a neurotrophic receptor tyrosine kinase (NTRK) gene fusion as determined by either: (i) occurring in a child less than 18 years of age; or (ii) being mammary analogue secretory carcinoma of the salivary gland; or (iii) being secretory breast carcinoma; and (b) the test is requested by a specialist or consultant physician to determine if requirements relating to NTRK gene fusion status for access to a tropomyosin receptor kinase (Trk) inhibitor under the Pharmaceutical Benefits Scheme are fulfilled This item cannot be claimed if item 73433 has been claimed for the same patient during the same cancer diagnosis Applicable only once per cancer diagnosis | 400.00 |
73431 | Two tests described in item 73430 | 533.00 |
73432 | Three or more tests described in item 73430 | 667.00 |
73433 | Next generation sequencing (NGS) test for neurotrophic receptor tyrosine kinase (NTRK1, NTRK2, NTRK3) fusions by RNA or DNA in tumour tissue from a patient with locally advanced or metastatic solid tumour, if: (a) the tumour is at risk of being caused by an NTRK gene fusion as determined by either: (i) occurring in a child less than 18 years of age; or (ii) being mammary analogue secretory carcinoma of the salivary gland; or (iii) being secretory breast carcinoma; (b) the test is requested by a specialist or consultant physician to determine if requirements relating to NTRK gene fusion status for access to a tropomyosin receptor kinase (Trk) inhibitor under the Pharmaceutical Benefits Scheme are fulfilled This item cannot be claimed if item 73430 has been claimed for the same patient during the same cancer diagnosis Applicable only once per cancer diagnosis | 1,000.00 |
73436 | A test of tumour tissue from a patient with a new diagnosis of non‑small cell lung cancer requested by, or on behalf of, a specialist or consultant physician, if the test is: (a) for MET proto-oncogene, receptor tyrosine kinase (MET) exon 14 skipping alterations (METex14sk) status to determine eligibility for access to a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73438 applies | 397.35 |
73437 | A nucleic acid‑based multi‑gene panel test of tumour tissue from a patient with a new diagnosis of non‑small cell lung cancer requested by, or on behalf of, a specialist or consultant physician, if the test is: (a) to detect variants in at least EGFR, BRAF, KRAS and MET exon 14 to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) to detect the fusion status of at least ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3 to determine eligibility for a relevant treatment under the PBS; and (c) not associated with a service to which item 73438, 73439, 73337, 73341, 73344, 73436 or 73351 applies | 1,247.00 |
73438 | A DNA‑based multi‑gene panel test of tumour tissue from a patient with a new diagnosis of non‑small cell lung cancer requested by, or on behalf of, a specialist or consultant physician, if the test is: (a) to detect variants in at least EGFR, BRAF, KRAS and MET exon 14; and (b) to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (c) not associated with a service to which item 73437, 73337, 73436 or 73351 applies | 682.35 |
73439 | A nucleic acid‑based multi‑gene panel test of tumour tissue from a patient with a new diagnosis of non‑small cell lung cancer and with documented absence of activating variants of the EGFR gene, KRAS, BRAF and MET exon14, requested by, or on behalf of, a specialist or consultant physician, if the test is: (a) for fusion status of at least ALK, ROS1, RET, NTRK1, NTRK2, and NTRK3 to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437, 73341, 73344 or 73351 applies | 682.35 |
Endnotes
Endnote 1—About the endnotes
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.
Editorial changes
The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.
If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the Legislation Act 2003.
If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.
Endnote 2—Abbreviation key
ad = added or inserted | orig = original |
am = amended | p = page(s) |
amdt = amendment | para = paragraph(s)/subparagraph(s) |
C[x] = Compilation No. x | /sub‑subparagraph(s) |
ch = Chapter(s) | pres = present |
cl = clause(s) | prev = previous |
cont. = continued | (prev…) = previously |
def = definition(s) | pt = Part(s) |
Dict = Dictionary | r = regulation(s)/Court rule(s) |
disallowed = disallowed by Parliament | reloc = relocated |
div = Division(s) | renum = renumbered |
ed = editorial change | rep = repealed |
exp = expires/expired or ceases/ceased to have | rs = repealed and substituted |
effect | s = section(s)/subsection(s) |
gaz = gazette | /rule(s)/subrule(s)/order(s)/suborder(s) |
LA = Legislation Act 2003 | sch = Schedule(s) |
LIA = Legislative Instruments Act 2003 | SLI = Select Legislative Instrument |
(md) = misdescribed amendment can be given | SR = Statutory Rules |
effect | sub ch = Sub‑Chapter(s) |
(md not incorp) = misdescribed amendment | sub div = Subdivision(s) |
cannot be given effect | sub pt = Subpart(s) |
mod = modified/modification | underlining = whole or part not |
No. = Number(s) | commenced or to be commenced |
Ord = Ordinance |
|
Endnote 3—Legislation history
Name | Registration | Commencement | Application, saving and transitional provisions |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Determination 2018 | 21 June 2018 (F2018L00810) | 1 July 2018 | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination 2018 | 26 October 2018 (F2018L01473) | 1 November 2018 | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination (No.2) 2018 | 30 October 2018 (F2018L01505) | 1 November 2018 | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination (No. 3) 2018 | 17 December 2018 (F2018L01776) | 1 January 2019 (s 2) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination 2019 | 17 January 2019 (F2019L00044) | 1 February 2019 (s 2) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination (No.2) 2019 | 22 February 2019 (F2019L00174) | 1 March 2019 (s 2) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination (No. 3) 2019 | 30 October 2019 (F2019L01385) | 1 November 2019 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination (No. 1) 2020 | 25 March 2020 (F2020L00304) | 1 April 2020 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination (No. 4) 2020 | 30 April 2020 (F2020L00521) | 1 May 2020 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination (No. 5) 2020 | 23 July 2020 (F2020L00938) | 1 August 2020 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination (No. 6) 2020 | 27 August 2020 (F2020L01075) | 1 September 2020 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination (No. 7) 2020 | 18 December 2020 (F2020L01642) | 1 January 2021 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination 2021 | 16 September 2021 (F2021L01270) | 1 November 2021 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination (No. 1) 2022 | 17 January 2022 (F2022L00033) | 1 January 2022 (s 2(1) item 2) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination (No. 2) 2022 | 31 March 2022 (F2022L00451) | 1 April 2022 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination (No. 3) 2022 | 30 June 2022 (F2022L00908) | 1 July 2022 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination (No. 4) 2022 | 22 August 2022 (F2022L01100) | 1 September 2022 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination (No. 5) 2022 | 26 September 2022 (F2022L01251) | 1 October 2022 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment Determination (No. 6) 2022 | 17 October 2022 (F2022L01358) | 1 November 2022 (s 2(1) item 1) | — |
Health Insurance Legislation Amendment (2023 Measures No. 2) Determination 2023 | 7 June 2023 (F2023L00731) | sch 3: 1 July 2023 (s 2(1) item 3) | — |
Health Insurance (Section 3C Co‑Dependant Pathology Services) Amendment Determination (No.1) 2023 | 24 August 2023 (F2023L01112) | 1 September 2023 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co‑Dependant Pathology) Amendment (No. 2) Determination 2023 | 22 September 2023 (F2023L01280) | 1 November 2023 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co‑Dependent Pathology) Amendment (No. 3) Determination 2023 | 14 December 2023 (F2023L01664) | 1 January 2024 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co‑Dependent Pathology Services) Amendment (No. 1) Determination 2024 | 20 May 2024 (F2024L00555) | 1 July 2024 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment (No. 2) Determination 2024 | 29 November 2024 (F2024L01528) | 1 January 2025 (s 2(1) item 1) | — |
Health Insurance Legislation Amendment (Indexation) Determination 2025 | 6 May 2025 (F2025L00554) | sch 2 (item 3): 1 July 2025 (s 2(1) item 1) | — |
Health Insurance Legislation Amendment (2025 Measures No.2) Determination 2025 | 30 May 2025 (F2025L00609) | sch 1 (item 1): 1 July 2025 (s 2(1) item 1) | — |
Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment (No. 1) Determination 2025 | 28 August 2025 (F2025L01002) | 1 November 2025 (s 2(1) item 1) | — |
Health Insurance Legislation Amendment (Indexation) Determination 2026 | 8 May 2026 (F2026L00523) | sch 1 (item 2): 1 July 2026 (s 2(1) item 2) | — |
Health Insurance Legislation Amendment (Listing of Futibatinib) Determination 2026 | 2 June 2026 (F2026L00632) | sch 1 (item 1): 1 July 2026 (s 2(1) item 1) | — |
Endnote 4—Amendment history
Provision affected | How affected |
s 2..................... | rep LA s 48D |
s 4..................... | rep LA s 48C |
s 5A.................... | ad F2026L00523 |
s 6..................... | am F2018L01505; F2025L01002 |
Schedule 1 |
|
Schedule 1................ | ad F2018L01473 |
| rs F2018L01505 |
| am F2018L01776; F2019L00044; F2019L00174; F2019L01385; F2020L00304; F2020L00521; F2020L00938; F2020L01075; F2020L01642; F2021L01270; F2022L00033; F2022L00451; F2022L00908; F2022L01100; F2022L01251; F2022L01358 |
| ed C17 |
| am F2023L00731; F2023L01112; F2023L01280; F2023L01664 |
| ed C21 |
| am F2024L00555; F2024L01528; F2025L00554 |
| ed C24 |
| am F2025L00609; F2025L01002 |
| ed C25 |
| am F2026L00632 |